13F Holdings
中文EN

APLM Apollomics Inc. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1944885 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY68.8%
TTM EPS YoY77.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-233.7%
ROA-157.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets—
Debt / equity0.00x
Current ratio1.39x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.53x
Accruals ratio-73.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31FY2020*2020-12-31
Income statement
Revenue$0$0$0$0$0
R&D expense$24.57M$34.19M$35.46M$35.57M$31.44M
Operating income——$976,000——
Interest expense$179,000$150,000$93,000$83,000$72,000
Pretax income-$53.60M-$172.59M-$240.81M-$94.80M-$74.91M
Income tax$259,000$10,000$1,000$1,000-$85,000
Net income-$53.86M-$172.60M-$240.81M-$94.80M-$74.82M
EPS (basic)-52.80-231.99-844.95-3.37-0.21
EPS (diluted)-52.80-231.99-844.95-3.37-0.21
Weighted avg. shares (diluted)1.02M744,000285,00028.11M361.48M
Balance sheet
Cash & equivalents$9.77M$32.06M$32.67M$46.74M$130.65M
Current assets$10.27M$39.92M$55.79M$99.37M—
PP&E, netmay include right-of-use assets (IFRS)$92,000$161,000$485,000$280,000—
Intangibles$1.74M$14.76M$14.78M$14.80M—
Total assets$13.10M$55.39M$76.47M$123.44M—
Current liabilities$7.40M$13.56M$12.36M$13.56M—
Short-term debt$0$4.24M———
Total liabilities——$448.12M——
Shareholders' equity$4.86M$41.23M-$448.12M-$212.86M-$127.93M
Cash flow statement
Operating cash flow-$28.74M-$43.21M-$42.82M-$43.31M-$35.68M
Capital expenditure$24,000$6,000$367,000$50,000$144,000
Free cash flow-$28.77M-$43.22M-$43.19M-$43.36M-$35.83M
Investing cash flow$5.98M$21.36M$29.05M-$38.95M$2.33M
Financing cash flow$468,000$21.23M-$294,000-$1.64M$125.51M
Stock-based compensation$10.93M$12.69M$3.58M$8.12M$4.51M
Dividends paid$0$0$0$0$0

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.